CN Patent

CN113164403A — 胶囊制剂

Assigned to Chemocentryx Inc · Expires 2021-07-23 · 5y expired

What this patent protects

本发明提供化合物1的固溶体胶囊制剂及其制备方法。本发明还提供了通过施用有效量的一个或多个包含化合物1的固溶体胶囊来治疗患有或易患与C5a受体病理性激活相关的疾病或病症的个体的方法。本发明还提供了包含一定量化合物1的单一单位剂量胶囊和包含含有化合物1的固溶体胶囊的试剂盒。

USPTO Abstract

本发明提供化合物1的固溶体胶囊制剂及其制备方法。本发明还提供了通过施用有效量的一个或多个包含化合物1的固溶体胶囊来治疗患有或易患与C5a受体病理性激活相关的疾病或病症的个体的方法。本发明还提供了包含一定量化合物1的单一单位剂量胶囊和包含含有化合物1的固溶体胶囊的试剂盒。

Drugs covered by this patent

Patent Metadata

Patent number
CN113164403A
Jurisdiction
CN
Classification
—
Expires
2021-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Chemocentryx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.